• #1212567
  • 14
  • AbbVie US LLC #00074501501

SKYRIZI® Risankizumab-rzaa 60 mg / mL Injection Single-Dose Vial 10 mL

SKYRIZI, SDV 600MG/10ML D/S

AbbVie US LLC 00074501501
AbbVie US LLC 00074501501
AbbVie US LLC 00074501501
SKYRIZI® Risankizumab-rzaa 60 mg / mL Injection Single-Dose Vial 10 mL
SKYRIZI® Risankizumab-rzaa 60 mg / mL Injection Single-Dose Vial 10 mL
SKYRIZI® Risankizumab-rzaa 60 mg / mL Injection Single-Dose Vial 10 mL
Compare
Features
  • SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
  • SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults
  • SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults
  • More …
Container Type
Single-Dose Prefilled Cartridge Single-Dose Vial
Strength
60 mg / mL 150 mg / mL
Type
Intravenous Subcutaneous
Volume
1.2 mL 2.4 mL 10 mL
Log In to Order
or
View Alternatives

Product Specifications

Features
  • SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
  • SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults
  • SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults
  • 600 mg/10 mL (60 mg/mL) single-dose vial

Professionals Also Viewed

  • #1194021
  • AbbVie Inc #00074105001
SKYRIZI® Risankizumab-rzaa 150 mg / mL Injection Prefilled Syringe 1 mL
  • SKYRIZI® is indicated for the treatment of moderate-to-severe plaque p …
  • Single-Dose Prefilled Syringe
  • #1194022
  • AbbVie Inc #00074210001
SKYRIZI® Risankizumab-rzaa 150 mg / mL Injection Prefilled Auto-Injector 1 mL
  • SKYRIZI® is indicated for the treatment of moderate-to-severe plaque p …
  • Single-Dose Pen
  • #1221601
  • AbbVie US LLC #0074106501
SKYRIZI® Risankizumab-rzaa 150 mg / mL Injection Single-Dose Prefilled Cartridge 1.2 mL
  • SKYRIZI® is indicated for the treatment of moderate-to-severe plaque p …
  • 180 mg/1.2 mL (150 mg/mL) single-dose prefilled cartridge with on-body …
  • # 1212568
  • AbbVie US LLC #00074107001
SKYRIZI® Risankizumab-rzaa 150 mg / mL Injection Single-Dose Prefilled Cartridge 2.4 mL
  • SKYRIZI® is indicated for the treatment of moderate-to-severe plaque p …
  • SKYRIZI is indicated for the treatment of active psoriatic arthritis i …
  • SKYRIZI is indicated for the treatment of moderately to severely activ …
Compare Products(0) Clear Compare